Integrating deep scientific expertise with a clear strategic vision to advance precision therapies for companion animals – enabling them to live healthier, happier, and longer lives.
Cancer and chronic immune-mediated diseases remain among the most significant unmet medical needs in companion animal health. While advances in human immuno-oncology have transformed outcomes for many patients, progress in veterinary medicine has lagged, with treatment options often relying on repurposed human drugs that are not optimised for species-specific biology. Vetigenics was founded to address this gap.
Vetigenics is a clinical-stage animal health biotechnology company developing species-specific, antibody-based immunotherapies for dogs and cats. The company’s targeted programmes are uniquely generated from a fully canine discovery platform to generate treatments offering measurable improvements in patient outcomes while prioritising safety, tolerability, and quality of life.
THE CANIBODY PLATFORM®: Purpose-built for veterinary medicine
Vetigenics’ CANIBODY Discovery Platform, a proprietary, fully canine phage display library, is a key differentiator that enables the discovery of antibodies naturally compatible with the canine immune system. In parallel, the company is also building a species-aware discovery strategy to support feline therapeutic development.
The CANIBODY Discovery Platform functions as a repeatable discovery engine, saving significant time and money getting to a lead candidate. The platform supports the simultaneous discovery of multiple unique candidates to quickly create a robust pipeline of high-value products in species-specific immunology.
Key capabilities include:
- Contains naturally occurring antibodies derived from actual dogs
- Rapid identification of high-affinity, target-specific antibodies tailored to species-specific immune biology
- Early candidate optimisation for developability saves time and money getting to a lead candidate
- Significantly reduces the risk of immunogenicity that can compromise long-term treatment
Advancing immuno-oncology and chronic immune-driven disease
Vetigenics has established itself as a leader in veterinary immuno-oncology. Cancer remains one of the leading causes of death in older dogs and cats, with limited treatment options that are often centered on chemotherapy. While chemotherapy can provide benefit, it is frequently associated with debilitating side effects and little survival advantage.
Vetigenics is among the first companies developing precision immunotherapies for companion animals that harness the animal’s own immune system to recognise and attack cancer cells. In human medicine, these approaches have demonstrated improved safety and survival benefits which Vetigenics aims to replicate for veterinary patients.
Beyond oncology, Vetigenics is advancing a broad and expanding pipeline of antibodies for autoimmune diseases, allergy, and osteoarthritis. These targeted, species-specific biologics have the potential to improve specificity, tolerability, and long-term disease control, creating opportunities to redefine standards of care in veterinary medicine.
A translationally inspired, companion-animal-first development model
Vetigenics was founded on principles inspired by translational medicine initiatives such as the Cancer Moonshot, which emphasised accelerating innovation through biologically relevant patient populations. Naturally occurring disease in dogs provides unique insight: canine patients share environmental exposures with humans, develop spontaneous cancers and chronic diseases with similar immune involvement, and receive care in clinically relevant settings.
While Vetigenics does not conduct human clinical studies, the company applies insights from human biomedical research to identify promising targets and guide therapeutic development in companion animals. Programmes include preclinical safety studies in research models and clinical evaluation in pet dogs and cats. Collaborations with veterinarians, veterinary oncologists, industry partners, and academic research institutions ensure Vetigenics’ products meet the needs of veterinary care today.
Through these partnerships, Vetigenics can:
- Design studies that mirror real-world veterinary practice
- Generate high-quality translational data from patient-derived samples
- Incorporate clinician and owner perspectives into trial design and clinical endpoints
This approach bridges discovery and clinical application, accelerating the path from antibody identification to therapies that meaningfully improve outcomes for companion animals.
Addressing external challenges in veterinary drug development
Veterinary biotechnology companies face unique structural challenges, including limited species-specific reagents, smaller patient populations for clinical studies, and a regulatory environment distinct from human drug development.
Vetigenics addresses these challenges proactively by investing in canine-specific assays, biomarker strategies, and immune monitoring tools – helping the company expand the ecosystem needed to support next-generation veterinary biologics.
Owner education and trust are equally important. Transparency around study design, sample collection, and the benefits of precision antibody therapy ensures Vetigenics’ innovation progresses alongside ethical responsibility, reinforcing confidence among veterinarians and pet owners.
Building toward the future of precision pet medicine
Looking ahead, Vetigenics envisions a future where precision medicine is an integral part of veterinary care, delivering durable value through species-specific biologics. Focus areas include:
- Expanding the antibody pipeline in areas of greatest unmet need
- Integrating immune profiling and biomarker-guided decision-making
- Identifying convenient and cost-effective drug delivery approaches
Strategic collaborations with academic groups, CROs, and industry partners allow Vetigenics to scale discovery, advance clinical programmes, and effectively bring novel therapies to market.
A mission-driven company
Vetigenics was founded on a simple but powerful mission: enabling pets to live their best lives. This mission extends beyond scientific milestones to supporting veterinarians, engaging pet owners, and continuously incorporating innovation to improve the lives of companion animals.
